S&P 500   3,936.97
DOW   32,030.11
QQQ   306.12
3 Dividend Contenders to Buy Now for Long-Term Gains Later
The gold catalyst we’ve waited for (Ad)
3 Tech Stocks Well Positioned For Growth At A Reasonable Price
These 3 Dividend Growers Yield More Than the 10-Year Note
Bank Accounts: Frozen! (Ad)
Closing prices for crude oil, gold and other commodities
Seesaw Effect: As Banks Drop, These 3 Stocks Are Going Up
The gold catalyst we’ve waited for (Ad)
AI Is Giving 3 Marketing & Ad Firms Revenue & Earnings Boost
Want Diversified Upside in Biotechnology? Check out LABU
S&P 500   3,936.97
DOW   32,030.11
QQQ   306.12
3 Dividend Contenders to Buy Now for Long-Term Gains Later
The gold catalyst we’ve waited for (Ad)
3 Tech Stocks Well Positioned For Growth At A Reasonable Price
These 3 Dividend Growers Yield More Than the 10-Year Note
Bank Accounts: Frozen! (Ad)
Closing prices for crude oil, gold and other commodities
Seesaw Effect: As Banks Drop, These 3 Stocks Are Going Up
The gold catalyst we’ve waited for (Ad)
AI Is Giving 3 Marketing & Ad Firms Revenue & Earnings Boost
Want Diversified Upside in Biotechnology? Check out LABU
S&P 500   3,936.97
DOW   32,030.11
QQQ   306.12
3 Dividend Contenders to Buy Now for Long-Term Gains Later
The gold catalyst we’ve waited for (Ad)
3 Tech Stocks Well Positioned For Growth At A Reasonable Price
These 3 Dividend Growers Yield More Than the 10-Year Note
Bank Accounts: Frozen! (Ad)
Closing prices for crude oil, gold and other commodities
Seesaw Effect: As Banks Drop, These 3 Stocks Are Going Up
The gold catalyst we’ve waited for (Ad)
AI Is Giving 3 Marketing & Ad Firms Revenue & Earnings Boost
Want Diversified Upside in Biotechnology? Check out LABU
S&P 500   3,936.97
DOW   32,030.11
QQQ   306.12
3 Dividend Contenders to Buy Now for Long-Term Gains Later
The gold catalyst we’ve waited for (Ad)
3 Tech Stocks Well Positioned For Growth At A Reasonable Price
These 3 Dividend Growers Yield More Than the 10-Year Note
Bank Accounts: Frozen! (Ad)
Closing prices for crude oil, gold and other commodities
Seesaw Effect: As Banks Drop, These 3 Stocks Are Going Up
The gold catalyst we’ve waited for (Ad)
AI Is Giving 3 Marketing & Ad Firms Revenue & Earnings Boost
Want Diversified Upside in Biotechnology? Check out LABU
NASDAQ:MRKR

Marker Therapeutics - MRKR Stock Forecast, Price & News

$1.20
-0.56 (-31.82%)
(As of 03/22/2023 12:00 AM ET)
Add
Compare
Today's Range
$1.11
$1.70
50-Day Range
$0.33
$3.12
52-Week Range
$1.11
$6.60
Volume
262,222 shs
Average Volume
46,498 shs
Market Capitalization
$10.03 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$1.50

Marker Therapeutics MarketRank™ Forecast

Analyst Rating
N/A
0.00 Rating Score
Upside/​Downside
25.0% Upside
$1.50 Price Target
Short Interest
Healthy
0.90% of Float Sold Short
Dividend Strength
N/A
Sustainability
-0.75
Upright™ Environmental Score
News Sentiment
-0.01mentions of Marker Therapeutics in the last 14 days
Based on 10 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
N/A

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.75 out of 5 stars

Medical Sector

773rd out of 986 stocks

Pharmaceutical Preparations Industry

370th out of 477 stocks


MRKR stock logo

About Marker Therapeutics (NASDAQ:MRKR) Stock

Marker Therapeutics, Inc. is a clinical-stage immuno-oncology company, which engages in the development and commercialization of novel cell-based immunotherapies and peptide-based vaccines for the treatment of hematological malignancies and solid tumor indications. The company was founded on October 22, 1991 and is headquartered in Houston, TX.

Receive MRKR Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Marker Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

MRKR Stock News Headlines

"Prepare for Five Years of Famine"
Market Wizard who predicted all indexes would be negative in 2022 shares shocking new forecast
Report on Marker Equipment Market Size until 2026
Buy THIS stock before Taiwan is attacked
... If the United States goes to war with another nuclear armed superpower, this could have a devastating impact on your retirement portfolio. Now, even Taiwan's own foreign minister is saying that China is on the cusp of a full scale invasion. But the good news is, if China invades Taiwan, there is a way to protect yourself.
See More Headlines
Receive MRKR Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Marker Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

MRKR Company Calendar

Last Earnings
11/10/2021
Today
3/22/2023
Next Earnings (Estimated)
3/23/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:MRKR
Fax
N/A
Employees
56
Year Founded
2018

Price Target and Rating

Average Stock Price Forecast
$1.50
High Stock Price Forecast
$1.50
Low Stock Price Forecast
$1.50
Forecasted Upside/Downside
+25.0%
Consensus Rating
N/A
Rating Score (0-4)
0.00
Research Coverage
0 Analysts

Profitability

Net Income
$-41,880,000.00
Net Margins
-515.88%
Pretax Margin
-515.89%

Debt

Sales & Book Value

Annual Sales
$1.24 million
Book Value
$5.29 per share

Miscellaneous

Free Float
6,086,000
Market Cap
$10.03 million
Optionable
Optionable
Beta
1.06

Social Links


Key Executives

  • Peter L. Hoang
    President, Chief Executive Officer & Director
  • Juan F. VeraJuan F. Vera
    Director, Chief Operating & Scientific Officer
  • Tsvetelina Pencheva Hoang
    Vice President-Research & Development
  • Mythili Koneru
    Chief Medical Officer
  • Gerald Garrett
    Vice President-Clinical Operations













MRKR Stock - Frequently Asked Questions

What is Marker Therapeutics' stock price forecast for 2023?

0 analysts have issued 1-year target prices for Marker Therapeutics' stock. Their MRKR share price forecasts range from $1.50 to $1.50. On average, they expect the company's stock price to reach $1.50 in the next twelve months. This suggests a possible upside of 25.0% from the stock's current price.
View analysts price targets for MRKR
or view top-rated stocks among Wall Street analysts.

How have MRKR shares performed in 2023?

Marker Therapeutics' stock was trading at $0.2659 on January 1st, 2023. Since then, MRKR shares have increased by 351.3% and is now trading at $1.20.
View the best growth stocks for 2023 here
.

Are investors shorting Marker Therapeutics?

Marker Therapeutics saw a increase in short interest in the month of February. As of February 28th, there was short interest totaling 65,400 shares, an increase of 64.3% from the February 13th total of 39,800 shares. Based on an average daily trading volume, of 38,500 shares, the short-interest ratio is presently 1.7 days. Currently, 0.9% of the shares of the company are sold short.
View Marker Therapeutics' Short Interest
.

When is Marker Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, March 23rd 2023.
View our MRKR earnings forecast
.

How were Marker Therapeutics' earnings last quarter?

Marker Therapeutics, Inc. (NASDAQ:MRKR) released its quarterly earnings data on Wednesday, November, 10th. The company reported ($0.12) EPS for the quarter, beating analysts' consensus estimates of ($0.13) by $0.01. Marker Therapeutics had a negative trailing twelve-month return on equity of 110.00% and a negative net margin of 515.88%.

What other stocks do shareholders of Marker Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Marker Therapeutics investors own include Amarin (AMRN), Viking Therapeutics (VKTX), PhaseBio Pharmaceuticals (PHAS), SCYNEXIS (SCYX), Matinas BioPharma (MTNB), Genocea Biosciences (GNCA), Strongbridge Biopharma (SBBP), Flexion Therapeutics (FLXN), Geron (GERN) and Ionis Pharmaceuticals (IONS).

What is Marker Therapeutics' stock symbol?

Marker Therapeutics trades on the NASDAQ under the ticker symbol "MRKR."

Who are Marker Therapeutics' major shareholders?

Marker Therapeutics' stock is owned by many different retail and institutional investors. Top institutional shareholders include Matrix Asset Advisors Inc. NY (0.30%), Millennium Management LLC (2.03%), Renaissance Technologies LLC (1.95%), Simplex Trading LLC (0.00%) and Concourse Financial Group Securities Inc. (0.00%). Insiders that own company stock include Frederick Gerald Wasserman, John Robert Wilson, Juan Vera, Paul Edward Walker and Peter L Hoang.
View institutional ownership trends
.

How do I buy shares of Marker Therapeutics?

Shares of MRKR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Marker Therapeutics' stock price today?

One share of MRKR stock can currently be purchased for approximately $1.20.

How much money does Marker Therapeutics make?

Marker Therapeutics (NASDAQ:MRKR) has a market capitalization of $10.03 million and generates $1.24 million in revenue each year. The company earns $-41,880,000.00 in net income (profit) each year or ($4.30) on an earnings per share basis.

How can I contact Marker Therapeutics?

Marker Therapeutics' mailing address is 3200 Southwest Freeway Suite 2240, Houston TX, 77027. The official website for the company is www.markertherapeutics.com. The company can be reached via phone at (713) 400-6400 or via email at investor.relations@markertherapeutics.com.

This page (NASDAQ:MRKR) was last updated on 3/23/2023 by MarketBeat.com Staff